Changes in lipid and carbohydrate metabolism under mTOR- and calcineurin-based immunosuppressive regimen in adult patients after liver transplantation

Zimmermann, Anthony; Zobeley, C; Weber, MM; Lang, H; Galle, PR; Zimmermann, Tim

doi:10.1055/s-0035-1567982

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 9 ] Patients receiving an mTOR-based chemotherapeutic regimen have a higher likelihood of developing dyslipidemia with increased atherogenic small dense Low-density Lipoproteins (sdLDLs). [ 10 ]…”

Section: How Do Anticancer Drugs Cause Ischemia?mentioning

confidence: 99%

Atherosclerosis, Ischemia, and Anticancer Drugs

Singh

Singh²

2021

Heart Views

View full text Add to dashboard Cite

The heart is affected by cardiotoxicity of anticancer drugs. Myocardium, pericardium and endocardium can be affected. Besides these coronary arteries can be affected by accelerated atherosclerosis. Various pathogenic mechanisms have been proposed that underlie the ischemic complications of anticancer drugs. In this review we discuss the atherosclerotic and ischemic complications of anticancer drugs.

show abstract

Section: How Do Anticancer Drugs Cause Ischemia?mentioning

confidence: 99%

Atherosclerosis, Ischemia, and Anticancer Drugs

Singh

Singh²

2021

Heart Views

View full text Add to dashboard Cite

show abstract

“…These risk factors often get exacerbated by immunosuppressive agents like steroids and CNI post LT. Finally, in few studies steatosis in donor liver has been shown to influence both the occurrence and progression of NAFLD in LT patients in few studies (6,(16)(17)(18)(19)(20).…”

Section: Risk Factors For the Development Of Nafld Post Liver Transplantmentioning

confidence: 99%

“…Immunosuppressive agents used post LT plays a significant role in MS in patients with NASH related LT. Insulin resistance which is a key component in MS is promoted by corticosteroids as it decreases peripheral glucose absorption, increase hepatic glucose production thereby increases risk of post-transplant diabetes. CNI, including cyclosporine and tacrolimus, are also diabetogenic in nature (20). Both steroid and CNI enhance the incidence of hypertension and dyslipidemia, promoting fatty liver in the graft liver.…”

Section: Risk Factors For the Development Of Nafld Post Liver Transplantmentioning

confidence: 99%

Approach to prevention of non-alcoholic fatty liver disease after liver transplantation

Sharma¹,

Arora²

2020

Transl Gastroenterol Hepatol

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) is one of the most common causes of liver disease and non-alcoholic steatohepatitis (NASH) related cirrhosis is third common indication for liver transplantation (LT). Patients who have NASH related cirrhosis and are candidates for LT often have multiple comorbidities.These comorbidities need to be addressed before and after transplantation as it affects overall survival. Like hepatitis B, hepatitis C, primary biliary cirrhosis, autoimmune hepatitis which recurs after transplantation, NASH also recurs after transplant however the impact of the recurrence on allograft and patient outcomes is unclear. Limited data suggests that it does not affect graft and patient survival. De novo NAFLD which is defined as occurrence of fatty liver in a patient who did not have fatty liver prior to LT can also occur in the allograft of patients transplanted for non-NAFLD liver disease. Obesity, hyperlipidemia, diabetes as well as steroid dose and duration after LT are common predictors of recurrence of NAFLD after transplantation.Studies on prevention and treatment of NASH in post-transplant patients are lacking. Prevention of weight gain, regular exercises, weight reducing surgery, limited steroid use or steroid free regimen have been tried with varying success. Future studies for the prevention of NAFLD/NASH are required especially in post liver transplant patient.

show abstract

Changes in lipid and carbohydrate metabolism under mTOR- and calcineurin-based immunosuppressive regimen in adult patients after liver transplantation

Cited by 2 publications

References 0 publications

Atherosclerosis, Ischemia, and Anticancer Drugs

Atherosclerosis, Ischemia, and Anticancer Drugs

Approach to prevention of non-alcoholic fatty liver disease after liver transplantation

Contact Info

Product

Resources

About